Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Varex Imaging (VREX) Research & Development (2016 - 2026)

Varex Imaging has reported Research & Development over the past 11 years, most recently at $21.7 million for Q1 2026.

  • Quarterly Research & Development fell 7.66% to $21.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $89.3 million through Jan 2026, down 0.78% year-over-year, with the annual reading at $91.1 million for FY2025, 4.71% up from the prior year.
  • Research & Development was $21.7 million for Q1 2026 at Varex Imaging, down from $24.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $24.2 million in Q4 2025 and troughed at $18.9 million in Q2 2022.
  • The 5-year median for Research & Development is $21.8 million (2023), against an average of $21.5 million.
  • Year-over-year, Research & Development rose 21.69% in 2023 and then fell 7.66% in 2026.
  • A 5-year view of Research & Development shows it stood at $20.0 million in 2022, then grew by 2.5% to $20.5 million in 2023, then rose by 6.83% to $21.9 million in 2024, then increased by 10.5% to $24.2 million in 2025, then dropped by 10.33% to $21.7 million in 2026.
  • Per Business Quant, the three most recent readings for VREX's Research & Development are $21.7 million (Q1 2026), $24.2 million (Q4 2025), and $21.4 million (Q3 2025).